期刊文献+

癃闭舒胶囊联合酒石酸托特罗定片治疗膀胱过度活动症的疗效 被引量:3

Retention of urine shu capsule in combination with tartaric acid tottenham luo certain curative effect on bladder hyperactive disorder
下载PDF
导出
摘要 目的:观察用癃闭舒胶囊联合酒石酸托特罗定片对膀胱过度活动症(OAB)患者进行治疗的临床效果。方法:将近年来某医院收治的128例女性OAB患者随机分为对照组和治疗组。在两组患者入院后,均使用酒石酸托特罗定片对其进行治疗。在此基础上,加用癃闭舒胶囊对治疗组患者进行治疗,然后对比两组患者治疗的效果。结果:接受治疗后两组患者的Qmax和Qave均高于接受治疗前,其VV均大于接受治疗前,其FUSS的评分均低于接受治疗前,而且治疗组患者的Qmax和Qave均高于对照组患者,其VV大于对照组患者,其FUSS的评分低于对照组患者,P<0.05。接受治疗期间两组患者均未出现严重的用药不良反应。结论:用癃闭舒胶囊联合酒石酸托特罗定片治疗OAB的效果确切、安全性高。 objective :to observe uroschesis shu capsule combined with tottenham Luo Ding treatment of female bladder disease curative effect of excessive activity.Methods :will be diagnosed 128 cases of female bladder disease patients were randomly divided into control group, 64 cases of excessive activity, giving tartrate tottenham Luo Ding 2 mg, twice a day. Treatment group 64 examples, giving tartrate tottenham Luo Ding 2 mg, 2 times a day and uroschesis shu capsule 3 pills, 2 times a day. 4 weeks after the determination of maximum urinary flow rate(Qmax) and average urinary flow rate(Qave), voiding volume(VV), urethral syndrome symptoms scale(USS) evaluation of curative effect.Results: two groups after treatment Qmax, Qave, VV, USS than before treatment significantly improved(P〈 0.01), the treatment group after treatment compared with control group after treatment, the indexes had significant difference(P〈 0.05).Conclusions:Retention of urine shu capsule combined with tottenham Luo Ding treatment of female bladder disease curative effect is distinct, excessive activity can significantly improve the patient's quality of life.
作者 陈保春 田龙江 李海燕 孙青风 刘利峰 CHEN Bao-chun;TIAN Long-jiang;LI Hai-yan;SUN Qingfeng;LIU Lifeng(Cangzhou city,hebei province people's hospital of hebei cangzhou 061000;Hebei cangzhou central hospital hebei cangzhou 061000)
出处 《当代医药论丛》 2018年第10期140-141,共2页
关键词 膀胱过度活动症 癃闭舒胶囊 酒石酸托特罗定片 Overactive Bladder women Difficulty in urination shu capsule Tottenham Luo Ding
  • 相关文献

参考文献6

二级参考文献30

  • 1张石革.选择性毒蕈碱M_3受体阻断剂进展与治疗膀胱过度活动症的评价[J].中国医院用药评价与分析,2007,7(4):246-250. 被引量:6
  • 2李新德,许力为,饶大庞.膀胱内注射肉毒素A治疗女性膀胱过度活动症的疗效探讨[J].中华泌尿外科杂志,2007,28(9):602-604. 被引量:6
  • 3Litwin MS McNaughton-Collins M,Fowler FJ Jr,et al.The National Institutis of Health chronic prostatitis symptom index:development and validation of a new outcome measure.Chronic Prostatitis Collaborative Research Network.[ J].J Urol,1999,1622):369-375.
  • 4陈新谦,金有豫.新编药物学[M].北京:人民卫生出版社,2006:21
  • 5CHUNG D E,TE A E.Toheredine extended-release for overactive bladder[J].Expert Opin Pharmacother,2009,10(13):2181-2194.
  • 6Hoebeke P, De Pooter J, De Caestecker K, et al. Solifenacin for Therapy Resistant Overactive Bladder[J]. JUro, 1 2009, 182 (4) : 2040-2044.
  • 7Milsom I,AbramsP,Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed: a populationbased prevalence study[J]. BJU Int 2001, 87(9) : 760- 766.
  • 8Chapple CR, Yamanishi T, Chess WR. Muscarinic receptor sub- types and management of the overactive bladder[J]. Urology, 2002, 60(Suppll) : 82-89.
  • 9Doiknoa C, Apellr A, Sandp K, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended- release formulations of oxybutynin and tolterodine for overactive bladder: resultsof the OPERA trial[J]. Mayo Clin Proc, 2003,78 (4) 5687-695.
  • 10Maruyama S, Oki T, Otsuka A,et al. Human muscarinic recep- tor binding characteristics of antlmuscarinic agents to treat over- active bladder[J]. J Urol,2006,175(1) :365.

共引文献159

同被引文献41

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部